Overview
Background
Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.
Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Qualifications
- Masters (Coursework) of Medical Science, University of Newcastle
- Royal Australasian College of Physicians, Royal Australasian College of Physicians
- Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia
Research impacts
The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.
Works
Search Professor Peter Mollee’s works on UQ eSpace
2009
Conference Publication
Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study
Mollee, Peter, Jones, Mark, Stackelroth, Jenny, van Kuilenburg, Rosita, Joubert, Warren, Faoagali, Joan, Looke, David, Harper, John and Clements, Archie (2009). Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: A prospective cohort study. 51st ASH Annual Meeting and Exposition, New Orleans, LA, U.S.A., 5-8 December 2009. Washington, DC, U.S.A.: American Society of Hematology.
2009
Conference Publication
WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaernia (AML)
Gray, J. X., McMillen, L., Saal, R., Lane, S., Mollee, P., Bird, R., Gill, D. and Marlton, P. (2009). WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaernia (AML). 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, United States, 5-8 December 2009. Washington, DC, United States: American Society of Hematology.
2009
Conference Publication
Sequential treatment with Rituximab and CHOP chemotherapy in B-Cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trial
Trappe, Ralf, Choquet, Sylvain, Oertel, Stephan H.K., Leblond, Veronique, Dierickx, Daan, Mollee, Peter, Sender, Monica, Ekman, Tor, Zaucha, Jan Maciej, Reinke, Petra, Neuhaus, Ruth, Lehmkuhl, Hans, Dreyling, Martin H., Duhrsen, Ulrich, Salles, Gilles, Morschhauser, Franck, Jaccard, Arnaud, Lamy, Thierry, Anagnostopoulos, Ioannis, Raphael, Martine, Dorken, Bernd and Riess, Hanno (2009). Sequential treatment with Rituximab and CHOP chemotherapy in B-Cell PTLD - moving forward to a first standard of care: Results from a prospective international multicenter trial. 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, United States, 5 - 8 December 2009. Washington, DC, United States: American Society of Hematology.
2008
Conference Publication
Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population
Keane, Colm G., Mollee, Peter, Marlton, Paula and Gill, Devinder (2008). Treatment of acute promyelocytic leukaemia in Jehovah’s Witness(JW) population. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.4014.4014
2008
Conference Publication
Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro
Gill, Devinder, Burgess, Melinda, Knop, Louise, Mollee, Peter and McMillan, Nigel (2008). Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro. 50th ASH Annual Meeting, San Francisco, CA United States, 6-9 December 2008. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v112.11.3157.3157
2008
Journal Article
A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation
Hourigan, Matthew J., Doecke, James, Mollee, Peter N., Gill, Devinder S., Norris, Debra, Johnson, David W. and Gandhi, Maher K. (2008). A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation. British Journal of Haematology, 141 (6), 904-907. doi: 10.1111/j.1365-2141.2008.07149.x
2008
Journal Article
Prolonged haematological toxicity from the hyper-CVAD regimen: Manifestations, frequency, and natural history in a cohort of 125 consecutive patients
Gill, Saar, Lane, Steven, Crawford, Julie, Cull, Gavin, Joske, David, Joske, David, Marlton, Paula, Mollee, Peter, Prince, Miles and Seymour, John (2008). Prolonged haematological toxicity from the hyper-CVAD regimen: Manifestations, frequency, and natural history in a cohort of 125 consecutive patients. Annals of Hematology, 87 (9), 727-734. doi: 10.1007/s00277-008-0488-6
2008
Journal Article
A 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor accute myeloid leukemia and predicts subsequent morphologic relapse
Lane, Steven, Saal, Russell, Mollee, Peter, Jones, Mark, Grigg, Andrew, Taylor, Kerry, Seymour, John, Kennedy, Glen, Williams, Bronwyn, Grimmett, Karen, Griffiths, Vanessa, Gill, Devinder, Hourigan, Matthew and Marlton, Paula (2008). A 1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor accute myeloid leukemia and predicts subsequent morphologic relapse. Leukemia & Lymphoma, 49 (3), 517-523. doi: 10.1080/10428190701817266
2008
Conference Publication
Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlations
Tate, J.R., Bazeley, S., Sykes, S. and Mollee, P. (2008). Serum free light chain assay for diagnosis and monitoring of monoclonal light-chain diseases - Analytical and clinical correlations. 60th Annual Meeting of the American Association for Clinical Chemistry, Washington, DC, United States, 27-31 July 2008. Washington, DC, United States: American Association for Clinical Chemistry.
2008
Conference Publication
Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro
Gill, Devinder, Burgess, Melinda, Knop, Louise, Mollee, Peter and McMillan, Nigel (2008). Identification of two novel chemokines (CCL2 and CXCL2) in B-chronic lymphocytic leukaemia (B-CLL) and prolonged survival of primary B-CLL cells in vitro. 50th Annual Meeting of the American- Society-of-Hematology, San Francisco, CA, United States, 6 - 9 December 2008. Washington, DC, United States: American Society of Hematology.
2007
Conference Publication
JAK2 V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET)
Weston, Helen, Bird, Robert, Griffiths, Vanessa, Jones, Mark, Grimmett, Karen, Saal, Russell, Mills, Anthony K., Gill, Devinder, Marlton, Paula and Mollee, Peter (2007). JAK2 V617F mutation status predicts thrombotic complications, including arterial thrombosis, in patients with essential thrombocytosis (ET). 49th ASH Annual Meeting, Atlanta, GA United States, 8-11 December 2007. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.v110.11.2551.2551
2007
Conference Publication
Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients
Mollee, Peter, Hourigan, Matthew, Johnson, David, Jones, Mark, Isbel, Nikki, Hawley, Carmel, Marlton, Paula, Gandhi, Maher, Campbell, Scott and Gill, Devinder (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. 49th Annual Meeting of the American-Society-of-Hematology, Atlanta, GA USA, 8-11 December 2007. Washington, DC USA: American Society of Hematology.
2007
Journal Article
Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis
Morris, K. L., Tate, J. R., Gill, D., Kennedy, G., Wellwood, J., Marlton, P., Bird, R., Mills, A. K. and Molle, P. (2007). Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Internal Medicine Journal, 37 (7), 456-463. doi: 10.1111/j.1445-5994.2007.01368.x
2007
Journal Article
Palifermin-induced Acanthosis Nigricans
Lane, S. W., Manoharan, S. and Mollee, P. N. (2007). Palifermin-induced Acanthosis Nigricans. Internal Medicine Journal, 37 (6), 417-418. doi: 10.1111/j.1445-5994.2007.01340.x
2007
Journal Article
Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders
Gandhi, M., Wilkie, G. M., Dua, U., Mollee, P., Grimmett, K., Williams, T., Whitaker, N., Gill, D. and Crawford, D. (2007). Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. American Journal of Transplantation, 7 (5), 1293-1299. doi: 10.1111/j.1600-6143.2007.01796.x
2007
Journal Article
Analytical performance of serum free light-chains assay
Tate, Jillian R., Mollee, Peter, Dimeski, Goce, Carter, Andrew C. and Gill, Devinder (2007). Analytical performance of serum free light-chains assay. Clinica Chimica Acta, 380 (1-2), 250-251. doi: 10.1016/j.cca.2007.02.004
2007
Journal Article
Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases
Tate, Jillian R., Mollee, Peter, Dimeski, Goce, Carter, Andrew C. and Gill, Devinder (2007). Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clinica Chimica Acta, 376 (1-2), 30-36. doi: 10.1016/j.cca.2006.07.011
2007
Journal Article
Epstein-Barr virus T-cell immunity despite rituximab
Nehring, Angela K., Dua, Ujjwal, Mollee, Peter, Gill, Devinder, Grimmett, Karen, Khanna, Rajiv, Moss, Denis and Gandhi, Maher K. (2007). Epstein-Barr virus T-cell immunity despite rituximab. British Journal of Haematology, 136 (4), 628-632. doi: 10.1111/j.1365-2141.2006.06482.x
2007
Conference Publication
Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients
Hourigan, Matthew J., Johnson, David W., Jones, Mark, Gill, Devinder S., Isbel, Nikki, Hawley, Carmel M., Marlton, Paula, Gandhi, Maher, Campbell, Scott B. and Mollee, Peter (2007). Immunosuppression (IST) can be safely ceased during chemotherapy for PTLD in renal transplant patients. American Transplant Congress, San Francisco, CA, USA, 5-9 May 2007. Oxford, England: Wiley-Blackwell. doi: 10.1111/j.1600-6143.2007.01811.x
2007
Conference Publication
Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II study
Trappe, R., Choquet, S., Oertel, S., LeBlond, V., Ekman, T., Sender, M., Mollee, P, Reinke, P., Lehmkuhl, H., Hummel, M., Jonas, S., Neuhaus, R., Salles, G., Morschhauser, F., Jaccard, A., Anagnostopoulos, I., Raphael, M. and Riess, H. (2007). Efficacy and safety of sequential treatment with rituximab and CHOP chemotherapy in B-cell PTLD: Results of a prospective international phase II study. Annual American Transplant Congress, San Francisco, CA, United States, 5 - 9 May 2007. Malden, MA, United States: Wiley-Blackwell Publishing. doi: 10.1111/j.1600-6143.2007.01811.x
Supervision
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Novel Radionuclide Tracers for Imaging in Amyloidosis
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
Doctor Philosophy
Addressing frailty in older people with haematological malignancies
Associate Advisor
Other advisors: Associate Professor Emily Gordon, Dr Natasha Reid, Professor Ruth Hubbard
Media
Enquiries
For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team: